Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,572 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biological Control Clear all
Completed Phase 2 Interventional

Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis

NCT04741087
View directory record Official record
Conditions
Pouchitis
Interventions
AMT-101 (oral)-Dose A, AMT-101 (oral)-Dose B
Drug
Lead sponsor
Applied Molecular Transport
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Bristol, Connecticut • Chicago, Illinois • Chevy Chase, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 21, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes

NCT01652716
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide once weekly suspension, Exenatide twice daily
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
58
States / cities
Muscle Shoals, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 21, 2026, 2:50 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis

NCT01809132
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
Anakinra, Pentoxifylline, Zinc Sulfate, Methylprednisolone
Drug
Lead sponsor
Mack Mitchell
Other
Eligibility
21 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Louisville, Kentucky • Worcester, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 21, 2026, 2:50 PM EDT
Completed Phase 2Phase 3 Interventional Results available

BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

NCT03482635
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Hamden, Connecticut • Miami, Florida • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 21, 2026, 2:50 PM EDT
Recruiting Phase 4 Interventional

Study of G-CSF for DOR in Patients Undergoing IVF

NCT07871825
View directory record Official record
Conditions
Diminished Ovarian Reserve, IVF, G-CSF, Granulocyte Colony Stimulating Factor
Interventions
Neupogen 300 μg subcutaneous injection, Subcutaneous injections of a saline solution
Drug · Other
Lead sponsor
Center for Human Reproduction
Other
Eligibility
35 Years to 44 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 2:50 PM EDT
Active, not recruiting Not applicable Interventional

Virtual Reality and Computerized Cognitive Intervention for Mild Cognitive Impairment in Heart Failure

NCT05601817
View directory record Official record
Conditions
Heart Failure, Mild Cognitive Impairment
Interventions
Vita, Com, Vita+Com
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
55 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 21, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

NCT03345836
View directory record Official record
Conditions
Crohn's Disease
Interventions
Matching Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
119
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 21, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Dysport in Hallux Abducto Valgus (HAV) Phase IIa

NCT03569098
View directory record Official record
Conditions
Hallux Abducto Valgus
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Castro Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 21, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

NCT01676116
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/liraglutide, liraglutide, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
85
States / cities
Birmingham, Alabama • Goodyear, Arizona • Mesa, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 21, 2026, 2:50 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

NCT03246529
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years to 78 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 21, 2026, 2:50 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

NCT04373031
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Pembrolizumab, IRX 2
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 21, 2026, 2:50 PM EDT
Active, not recruiting Phase 1 Interventional

Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants

NCT07350577
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
ALTB-268, Placebo
Biological · Other
Lead sponsor
AltruBio Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 21, 2026, 2:50 PM EDT
Completed Not applicable Interventional

Nutrient Levels Alter Transplant Outcome

NCT00560014
View directory record Official record
Conditions
Chronic Renal Disease
Interventions
Arginine and canola oil, Coromega and Arginine
Dietary Supplement
Lead sponsor
University of Cincinnati
Other
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2007 · Synced Oct 21, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

NCT00044694
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Placebo 0.01 mL, Placebo 0.02 mL, Placebo 0.03 mL, Placebo 0.04 mL, AC2993 2.5 mcg, AC2993 5.0 mcg, AC2993 7.5 mcg, AC2993 10.0 mcg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
33
States / cities
Birmingham, Alabama • Anaheim, California • Bellflower, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 21, 2026, 2:50 PM EDT
Terminated Not applicable Interventional

Randomized Control Trial of L-Alanine and Placebo in Fructose Intolerance

NCT01288495
View directory record Official record
Conditions
Dietary Fructose Intolerance
Interventions
supplemental L-alanine, Metamucil
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 21, 2026, 2:50 PM EDT
Completed Phase 2 Interventional Results available

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

NCT01373294
View directory record Official record
Conditions
Bladder Cancer
Interventions
Bacille Calmette-Guerrin (BCG), Lenalidomide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 21, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

NCT00770029
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
IncobotulinumtoxinA (Xeomin) (20 Units), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Meatrie, Louisiana • Chestnut Hill, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 21, 2026, 2:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adipokines Effect in Myometrial Contractility

NCT03505541
View directory record Official record
Conditions
Myometrium; Contractility, GDM, Obesity
Interventions
Adiponectin and TNFa
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 21, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of a Flu Vaccine in Children

NCT00001127
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (CAIV-T)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Months to 18 Years
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 21, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

NCT00085969
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo 0.04 mL twice daily, Placebo 0.04 mL once daily, Placebo 0.08 mL once daily, B - Exenatide 10 mcg twice daily, C - Exenatide 10 mcg once daily, Exenatide 20 mcg once daily
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 21, 2026, 2:50 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

NCT03014622
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A, Placebos
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 21, 2026, 2:50 PM EDT
Completed Phase 2 Interventional

A Randomized, Control Trial for Preinduction Cervical Ripening

NCT00393731
View directory record Official record
Conditions
Labor, Induced
Interventions
Misoprostol, oxytocin
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Female only
Enrollment
540 participants
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2008 · Synced Oct 21, 2026, 2:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response

NCT01301001
View directory record Official record
Conditions
Vulvodynia
Interventions
Placebo oral capsule, Gabapentin
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
New Brunswick, New Jersey • Rochester, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 21, 2026, 2:50 PM EDT
Recruiting Not applicable Interventional

The RESET System Pivotal Clinical Trial (Protocol Revision K)

NCT04101669
View directory record Official record
Conditions
Diabetes type2, Obesity
Interventions
RESET Liner, Sham
Device · Other
Lead sponsor
Morphic Medical Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
27
States / cities
Gilbert, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 2:50 PM EDT